About: drug pricing

Health 04-12-2018

Greek pharma boss: ‘We reached our limits, our sustainability is at stake’

The Greek pharmaceutical industry has reached its limits due to a number of “unreasonable” burdens imposed by the government during the crisis, Greek pharma chief Olympios Papadimitriou told EURACTIV.com in an interview. The sustainability of pharma companies is at stake, threatening 86,000 jobs, he said.
Health 10-07-2018

Investment in digital health and access to drugs at the core of Austrian Presidency

Austria’s EU Presidency will focus on “strong” investment in digital health as well as on regulatory issues when it comes to access to medicines, Dr Clemens Martin Auer told EURACTIV.com in an interview. Dr Clemens Martin Auer is the president of the...
Health 03-07-2018

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  
Health 29-01-2018

Health expert: Europe should not put its dominant pharma innovation at risk

The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.
Health 07-12-2017

Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped

Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.
Health 04-10-2017

Gastein boss: Drugs access is ‘sensitive’ and cannot be viewed in isolation

Accessibility of medicines is a sensitive issue that must not be examined in isolation. Policymakers, academics, business and patients must be part of the discussion as well as “innovation” because access would not get the focus it needs without it, according to Dorli Kahr-Gottlieb.
Health 17-03-2017

Pharma boss: Some EU countries effectively delay market entry of generics

The harmonisation of different regulatory environments in the EU member states will help generic drugs enter the market, resulting in reduced prices for medicine and better patient access, Jacek Glinka told EURACTIV.com in an interview.

Want to know what's going on in the EU Capitals daily? Subscribe now to our new 9am newsletter.